News
-
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
-
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
-
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
-
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
-
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
-
AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study
-
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
-
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones
-
ONL Therapeutics Names Connie Chang as Chief Operating Officer